Navigation Links
TGen and Virginia G. Piper Cancer Center form drug development collaboration with Cedars-Sinai

SCOTTSDALE, Ariz. -- The Virginia G. Piper Cancer Center at Scottsdale Healthcare is expanding its efforts to accelerate advances in cancer care with the addition of Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute in Los Angeles as a collaborator in clinical trials to develop personalized therapies that could lead to more effective cancer treatments.

The collaboration will focus on Phase I clinical trials of new personalized therapies for a variety of rare and common cancers, focusing on three areas of cancer research:

  • Gastrointestinal malignancies including pancreatic, colorectal and gastric cancer
  • Genitourinary malignancies such as prostate, kidney and bladder cancer
  • Rare cancers including adrenal, neuroendocrine and thyroid cancer

Virginia G. Piper Cancer Center Clinical Trials, a partnership between the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, will provide local coordination for the program. The partnership offers patients access to promising new cancer treatments through clinical trials, emphasizing collaboration among leading organizations to speed innovation from laboratory bench to patient bedside.

The collaborative endeavor between TGen, Virginia G. Piper Cancer Center and Cedars-Sinai also will study new approaches to improve patients' quality of life during cancer treatment and create innovative models to deliver supportive care and services to cancer survivors.

The Virginia G. Piper Cancer Center at Scottsdale Healthcare serves the greater Phoenix area with innovative cancer treatment and research facilities that attract patients from across Arizona and the United States.

"In addition to our local patients a significant number travel from the west coast for treatment at the Virginia G. Piper Cancer Center. The opportunity to expand our collective efforts against these cancers will undoubtedly mean progress in medicine's ability to successfully treat the disease," said Dr. Ramesh Ramanathan, M.D., Medical Director, Virginia G. Piper Cancer Center Clinical Trials, and Deputy Director of TGen's Clinical Translational Research Division.

Cedars-Sinai is the largest academic medical center in the western U.S. Its outpatient cancer center treats more than 9,000 patients each year, making it one of the busiest treatment facilities in California. Earlier this year, U.S. News & World Report named the institute's cancer program as one of the top in the country.

"Our two organizations share the same goal: to greatly improve cancer treatment with therapies that attack the disease in new and innovative ways," added Steven Piantadosi, M.D., Ph.D., Phase One Foundation chair and director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center. "Translating new research into effective therapies will improve the lives of cancer patients, and, ultimately, lead to a time when cancer is a manageable condition not a feared disease."

The Virginia G. Piper Cancer Center at Scottsdale Healthcare opened in December 2001 as the first comprehensive cancer center in greater Phoenix and ranks as one of the country's leading programs for new cancer drug development and Phase I studies.

"We are very excited about this new collaboration intended to accelerate development of new ways to beat cancer," said Tom Sadvary, president & CEO of Scottsdale Healthcare. "Our two organizations share the same commitment to improving the lives of our patients and expanding the ever-increasing number of cancer survivors."

Individuals seeking information about eligibility to participate in clinical trials at the Virginia G. Piper Cancer Center at Scottsdale Healthcare may contact the cancer care coordinator at 480-323-1339; toll free at 1-877-273-3713; or via email at

Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related medicine news :

1. Virginia Commonwealth University findings may help explain high blood pressure in pregnancy
2. Virginia Commonwealth University study: We are what we experience
3. TGen/Virginia G. Piper Cancer Center publish results of new drug for pancreatic cancer patients
4. TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer
5. Months After Shootings, Many Virginia Tech Students Suffered PTSD
6. TGen, Virginia G. Piper Cancer Center studying new breast cancer drug
7. VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission
8. Virginia Bioinformatics Institute to model immune responses to gut pathogens
9. Virginia Tech professor discovers new TB pathogen
10. VCU first Virginia institution to join national network of academic research centers
11. Dr. Phillip Chang Introduces New Ways to Decrease Scars and Potential Complications For Breast Augmentations in Loudoun and Fairfax Virginia
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: